Abstract #3632

Differentiating Pseudoprogression from True Progression Using DTI and DSC-MRI

Sumei Wang¹, Sanjeev Chawla¹, Sungheon Kim², Arati Desai³, Michelle Alonso-Basanta⁴, Maria Martinez-Lage⁵, Steven Brem⁶, Elias R. Melhem¹,⁷, Harish Poptani¹

¹Radiology, University of Pennsylvania, Philadelphia, PA, United States; ²Radiology, New York University School of Medicine, New York, NY, United States; ³Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, United States; ⁴Radiation Oncology, University of Pennsylvania, Philadelphia, PA, United States; ⁵Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States; ⁶Neurosurgery, University of Pennsylvania, Philadelphia, PA, United States; ⁷Radiology, University of Maryland, Baltimore, MD, United States

The purpose of this study was to determine whether diffusion and perfusion MRI can help in differentiating pseudoprogression (PsP) from true progression (TP) in glioblastoma patients demonstrating enhancing lesions within six months post chemo-radiation therapy. Six patients with PsP and 7 patients with TP underwent DTI and DSC-MRI studies. Significantly elevated median mean diffusivity (MD) and decreased rCBV from the enhancing part of the tumor was observed in patients with PsP compared with TP, indicating that DTI and DSC may be helpful in differentiating PsP from TP.